Navigation Links
Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals
Date:9/20/2010

cal industry; our dependence on a small number of products and on outside manufacturers for the manufacture of our products; our dependence on third parties to supply raw materials and to provide services for certain core aspects of our business; new regulatory action or lawsuits relating to our use of controlled substances in many of our core products; our exposure to product liability claims and product recalls and the possibility that we may not be able to adequately insure ourselves; our ability to protect our proprietary technology; our ability to successfully implement our in-licensing and acquisition strategy; the availability of third-party reimbursement for our products; the outcome of any pending or future litigation or claims by the government; our dependence on sales to a limited number of large pharmacy chains and wholesale drug distributors for a large portion of our total net sales; a determination by a regulatory agency that we are engaging in inappropriate sales or marketing activities, including promoting the "off-label" use of our products; the loss of branded product exclusivity periods and related intellectual property; and exposure to securities that are subject to market risk including auction-rate securities the market for which is currently illiquid; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS" in our annual report on Form 10-K for the year ended Dec. 31, 2009, which was filed with the Securities and Exchange Commission on Feb. 26, 2010. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and h
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NewBridge Pharmaceuticals Completes $12 Million First Close of Series B Financing, Announces Senior Executive Appointments
2. Lead Plaintiffs Attorney In Forest Pharmaceuticals Case Says $313 Million Award Is Tip of the Iceberg of Future Off-Label Marketing Lawsuits
3. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
4. HRA Pharma and Watson Pharmaceuticals Expand Marketing Partnership for Novel Emergency Contraceptive to Canada
5. Onyx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
6. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
7. ISTA Pharmaceuticals Initiates Phase 3 Clinical Program for REMURA™ in Dry Eye Disease
8. Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws
9. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
10. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
11. Access Pharmaceuticals Launches MuGard Product Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 21, 2014 ... the European Medicines Agency (EMA) has granted ... company,s lead product candidate, for the treatment ... a rare, severely disabling genetic disease characterized ... swelling (flare-ups) and new abnormal bone formation. ...
(Date:11/21/2014)... LITTLE FALLS, N.J. , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL ... Andrew A. Krakauer , Chief Executive Officer, will be presenting ... at The New York Palace Hotel in New ... December 2, 2014 at 2:00 PM ET. In addition, Mr. ... will be available for separate one-on-one meetings during the day. ...
(Date:11/21/2014)... November 2014 Michael DeMarco (42) ... des 14. Februar 2014 zugetragen hat. Seine Tochter Aly ... Video - http://youtu.be/5cVoMCe0uiE ... mein morgendliches Training zu machen", erzählt Michael DeMarco ... Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3
... Inc. (Nasdaq: OMCL ) a leading provider of ... present at the UBS 21st Annual Global Healthcare Services Conference ... Omnicell Speakers: Rob Seim, vice president & CFO ... Tuesday, February 8, 2011Time: 11:00 a.m. ESTLocation: Grand ...
... 2011 Carrot Medical, a leading designer of integrated ... During the year, Carrot Medical achieved significant growth in ... private financing. Carrot Medical, recognized as a ... Technology solution that integrates medical images and other visual ...
Cached Medicine Technology:Omnicell to Present at the UBS 21st Annual Global Healthcare Services Conference 2Carrot Medical Reports 2010 Growth in Sales and Financing, Optimism for 2011 2
(Date:11/21/2014)... Porcelain veneer dentist, Dr. ... in preparation for the coming holiday season. Veneers, ultra-thin ... look completely natural, and can be used to permanently ... valued for their ability to strengthen teeth. Veneers are ... on one or several teeth to rejuvenate appearance. Check ...
(Date:11/21/2014)... Nov. 20, 2014 (HealthDay News) -- Seeking to make ... U.S. Food and Drug Administration on Thursday approved a ... Hydrocodone -- best known by the brand name ... been tied to a surge in dangerous addictions across ... approved Hysingla ER (hydrocodone bitartrate) is an extended-release tablet ...
(Date:11/21/2014)... 2014 (HealthDay News) -- Certain genes might prevent regular ... a fifth of people with type 2 diabetes, a ... pondered by doctors working with diabetic patients, one expert ... the impression that exercise helps decrease insulin resistance in ... director of the Center for Weight Management at North ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 Richard ... Solutions , will present advanced benefits administration strategies ... Annual Houston HR Leadership Summit. This Game Changer ... Resources industry to present cutting-edge solutions and best ... will explain how real-time data exchange between health ...
(Date:11/21/2014)... WOBURN, Mass. (PRWEB) November 21, 2014 ... two free workshops titled “Massachusetts Insurance Funding for Autism ... disorder (ASD) navigate their way through the insurance coverage ... covered under Massachusetts law and the most effective ways ... on Thursday, Dec. 4 from 6-8:00 p.m. at 331 ...
Breaking Medicine News(10 mins):Health News:Los Angeles Porcelain Veneers Dentist, Dr. Kevin Sands, Now Creates Picture-Perfect Smiles for Patients for the Holiday Season 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 3Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 2Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 3Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 2Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 3Health News:Center for Autism and Related Disorders to Host Massachusetts Autism Insurance Workshops for Parents 2
... Associates will host a community health fair in the Shoh-Sohail ... will include free health screenings for the local community, will ... VHA Building on the Mandalay Canal, 220 Las Colinas Blvd, ... will be hosted in an effort to inform, educate and ...
... the availability of Trade Alerts on stocks making news today. ... free by visiting: http://www.BeaconEquity.com/m Today,s Trade Alerts include: ... (NYSE: ABT ), Eli Lilly & Co. (NYSE: ... ), Novartis AG (NYSE: NVS ) and GlaxoSmithKline ...
... Feb. 18 SpectraScience, Inc. (OTC Bulletin Board: ... it will place its LUMA(R) Cervical Imaging System ... located in Edina, Minnesota.Dr. James B. Presthus, co-founder ... of the LUMA System represents our continued dedication ...
... affairs departments in deploying comprehensive investigator-initiated research grant management program ... ... 18, 2009 -- Clinipace, a growing clinical research solutions company, ... firms to deploy its TEMPO™ for Grant Management ...
... is warranted, experts say , , WEDNESDAY, Feb. 18 (HealthDay News) ... human fetal stem cell therapy has been reported in Moscow, ... to the growths. , The tumors appeared along ... after he began receiving the neural fetal stem cell treatment ...
... Feb. 18 Inverness Medical Innovations, Inc. (NYSE: ... charge of their health at home through the merger of ... for the quarter ended December 31, 2008.In the fourth quarter ... compared to net revenue of $288.0 million in the fourth ...
Cached Medicine News:Health News:Las Colinas FREE Community Health Fair Benefiting the Shoh-Sohail Family of Irving 2Health News:Beacon Equity Issues Technical Trade Alerts on Drug Manufacturers: JNJ, ABT, LLY, PFE, NVS, GSK 2Health News:LUMA Cervical Imaging System Installed in Edina at Minnesota Gynecology 2Health News:LUMA Cervical Imaging System Installed in Edina at Minnesota Gynecology 3Health News:Two Pharmaceutical Firms Select Clinipace to Deploy New Grant Management Solution 2Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 2Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 3Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 4Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 5Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 6Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 7Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 8Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 9Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 10Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 11Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 12Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 13Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 14Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 15Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 16Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 17Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 18
BD Beaver Phaco slit blade, 3.2 mm, angled 45, bevel up. matte finish offers a precise incision which minimizes leakage during phaco procedures. Precise incision minimizes leakage during phaco proced...
BD Beaver DeBakey blade, 5 mm cutting width, sterile....
... testing of large oculomotor imbalances ... all standard trial frames. Offer ... thin optical quality acrylic and ... a display box. Available as ...
... only powered 6-inch dermatome on the market. ... adult hands or a small child's face ... to run more efficiently, thus the motor ... temperature is much cooler. The Electro-Dermatome is ...
Medicine Products: